Cardio Diagnostics Holdings, Inc. (CDIO): Capital Expenditures
$187.3K
Year ended 2025-12-31
$164.6K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $187.3K | -12.8% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $214.8K | -62.7% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $575.7K | n/a | 2025-03-20, From 2023-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $187.3K | -12.8% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $2.71M | +41.4% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $89.6K | -67.7% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $3.19M | +517.2% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $16.0K | -56.8% |
| Immucell Corp (ICCC) | 2025-12-31 | $1.25M | +168.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $1.15M | +2.0% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $1.13M | -80.5% |
| Neogen Corp (NEOG) | 2026-05-31 | $51.30M | -51.0% |
Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗